The short version of AOD-9604 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-15 and is reviewed periodically as new material appears.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
== Sources == Ovington LG (October 2002). "The evolution of wound management: ancient origins and advances of the past 20 years". Home Healthc Nurse. 20 (10): 652–6. doi:10.1097/00004045-200210000-00009. PMID 12394337. Sipos P, Gyõry H, Hagymási K, Ondrejka P, Blázovics A (February 2004). "Special wound healing methods used in ancient egypt and the mythological background". World J Surg. 28 (2): 211–6. doi:10.1007/s00268-003-7073-x. PMID 14708054. S2CID 1210892. "Dressing and Bandage Types." Wound Care. N.p., n.d. Web. 23 Nov. 2015.
==== Pharmacokinetics ==== Due to high lipid solubility, cannabidiol is poorly absorbed in the intestine. The absorbed cannabidiol accumulates in adipose tissue or albumin (proteins in blood), which prolongs its elimination from the body. Most absorbed cannabidiol is converted into other metabolites by various enzymes in the liver and intestine, including CYP2C19 and CYP3A4. Cannabidiol is mainly excreted from the body with faeces.
Life arose on Earth once it had cooled enough for oceans to form. That developed into the last universal common ancestor (LUCA), an organism which had ribosomes and the genetic code, some 3.5-4 billion years ago. It gave rise to two domains of life, the bacteria and the archaea. From among these small-celled ancestors arose the eukaryotes, with a much wider range of cell sizes, and more complex cells with nuclei, a cytoskeleton, and an endomembrane system. The eukaryotes form a third domain that contains all complex cells and most types of multicellular organisms, including the animals, plants, and fungi. The last eukaryotic common ancestor (LECA) is the hypothetical most recent common ancestor of all living eukaryotes, around 2 billion years ago, and was most likely a biological population. It is not known how the bacteria and archaea gave rise to the LECA (and hence to all later eukaryotes) in the process of eukaryogenesis, as the fossil record of ancient single-celled organisms is fragmentary. Instead biologists have focused on reconstructing the properties of the LECA from what is known of the genomes of different lineages of modern eukaryotes.
A recent droplet-PCR PDMS device allowed for higher accuracy and amplification of small copy numbers in comparison to traditional quantitative PCR experiments. This higher accuracy was due to surfactant-doped PDMS as well as a sandwiched glass-PDMS-glass device design. These device properties have allowed for more streamlined priming of DNA and less water evaporation during PCR cycling.
Sources: en.wikipedia.org
Aspartic acid, for example, possesses one protonated amine and two deprotonated carboxyl groups, for a net charge of −1 at physiological pH. Fatty acids and fatty acid derivatives are another group of carboxylic acids that play a significant role in biology. These contain long hydrocarbon chains and a carboxylic acid group on one end. The cell membrane of nearly all organisms is primarily made up of a phospholipid bilayer, a micelle of hydrophobic fatty acid esters with polar, hydrophilic phosphate "head" groups. Membranes contain additional components, some of which can participate in acid–base reactions. In humans and many other animals, hydrochloric acid is a part of the gastric acid secreted within the stomach to help hydrolyze proteins and polysaccharides, as well as converting the inactive pro-enzyme, pepsinogen into the enzyme, pepsin. Some organisms produce acids for defense; for example, ants produce formic acid. Acid–base equilibrium plays a critical role in regulating mammalian breathing. Oxygen gas (O2) drives cellular respiration, the process by which animals release the chemical potential energy stored in food, producing carbon dioxide (CO2) as a byproduct. Oxygen and carbon dioxide are exchanged in the lungs, and the body responds to changing energy demands by adjusting the rate of ventilation. For example, during periods of exertion the body rapidly breaks down stored carbohydrates and fat, releasing CO2 into the blood stream. In aqueous solutions such as blood CO2 exists in equilibrium with carbonic acid and bicarbonate ion.
The effects on the federal budget of the aging population and rapidly growing health care costs are already apparent over the 10-year horizon—especially for Social Security and Medicare—and will grow in size beyond the baseline period. Unless laws governing fiscal policy were changed—that is, spending for large benefit programs was reduced, increases in revenues were implemented, or some combination of those approaches was adopted—debt would rise sharply relative to GDP after 2027. During June 2012, Federal Reserve Chair Ben Bernanke recommended three objectives for fiscal policy: 1) Take steps to put the federal budget on a sustainable fiscal path; 2) Avoid unnecessarily impeding the ongoing economic recovery; and 3) Design tax policies and spending programs to promote a stronger economy. President Barack Obama in June 2012 stated:
== History == Before the development of the ELISA, the only option for conducting an immunoassay was radioimmunoassay, a technique using radioactively labeled antigens or antibodies. In radioimmunoassay, the radioactivity provides the signal, which indicates whether a specific antigen or antibody is present in the sample. Radioimmunoassay was first described in a scientific paper by Rosalyn Sussman Yalow and Solomon Berson published in 1960. As radioactivity poses a potential health threat, a safer alternative was sought. A suitable alternative to radioimmunoassay would substitute a nonradioactive signal in place of the radioactive signal. When enzymes (such as horseradish peroxidase) react with appropriate substrates (such as ABTS or TMB), a change in color occurs, which is used as a signal. However, the signal has to be associated with the presence of an antibody or antigen, which is why the enzyme has to be linked to an appropriate antibody. This linking process was independently developed by Stratis Avrameas and G. B. Pierce. Since it is necessary to remove any unbound antibody or antigen by washing, the antibody or antigen has to be fixed to the surface of the container; i.e., the immunosorbent must be prepared. A technique to accomplish this was published by Wide and Jerker Porath in 1966. In 1971, Peter Perlmann and Eva Engvall at Stockholm University in Sweden, and Anton Schuurs and Bauke van Weemen in the Netherlands independently published papers that synthesized this knowledge into methods to perform EIA/ELISA.
=== Legacy === De Duve founded a multidisciplinary biomedical research institute at Université catholique de Louvain in 1974, originally named the International Institute of Cellular and Molecular Pathology (ICP). He remained its president until 1991. On his 80th birthday in 1997 it was renamed the Christian de Duve Institute of Cellular Pathology. In 2005 its name was further contracted to simply the de Duve Institute. De Duve was one of the founding members of the Belgian Society of Biochemistry and Molecular Biology, established on 15 September 1951. De Duve is remembered as an inventor of important scientific terminology. He coined the word lysosome in 1955, peroxisome in 1966, and autophagy, endocytosis, and exocytosis in one instance at the Ciba Foundation Symposium on Lysosomes held in London during 12–14 February 1963, while he, "was in a word-coining mood." De Duve's life, including his work resulting in a Nobel Prize, and his passion for biology is the subject of a documentary film Portrait of a Nobel Prize: Christian de Duve (Portrait de Nobel : Christian de Duve), directed by Aurélie Wijnants. It was first aired on Eurochannel in 2012.
=== EC 1.6.99 With unknown physiological acceptors === EC 1.6.99.1: NADPH dehydrogenase EC 1.6.99.2: Now EC 1.6.5.2, NAD(P)H dehydrogenase (quinone EC 1.6.99.3: The activity is covered by EC 7.1.1.2, NADH:ubiquinone reductase (H+-translocating) EC 1.6.99.4: Now EC 1.18.1.2, ferredoxin—NADP+ reductase EC 1.6.99.5: Now EC 1.6.5.11, NADH dehydrogenase (quinone) EC 1.6.99.6: Now EC 1.6.5.10, NADPH dehydrogenase (quinone) EC 1.6.99.7: Now EC 1.5.1.34, 6,7-dihydropteridine reductase EC 1.6.99.8: Deleted EC 1.6.99.9: Now EC 1.16.1.4, cob(II)alamin reductase EC 1.6.99.10: included in EC 1.5.1.34, 6,7-dihydropteridine reductase EC 1.6.99.11: Deleted EC 1.6.99.12: Now EC 1.16.1.6, cyanocobalamin reductase (cyanide-eliminating) EC 1.6.99.13: Now EC 1.16.1.7, ferric-chelate reductase
Sources: en.wikipedia.org
=== Accessory foramina === Accessory foramina are small openings, distinct from the main physiological foramen, which connect the root canal system to the periapical tissue through accessory canals. In micro-computed tomography (micro-CT) studies, they are often defined quantitatively, such as any apical foramen with a diameter smaller than 0.2 mm. Their prevalence varies significantly among different teeth. Research on mandibular canines found that approximately one-third of specimens had at least one accessory foramen. Studies of other tooth types confirm that accessory canals and their foramina are a common anatomical feature, especially in the apical region of roots. Due to their minute size, detailed visualization of accessory foramina is best achieved using high-resolution ex vivo imaging techniques like micro-CT, which is considered a gold standard for such morphological analysis.
These studies have produced models of protein adhesive and other biopolymer deteriorations and the concurrent pore system development. The reduction in bodily repair capability during aging is important to studies of senescence and age-associated disease, and allows the determination of age in living animals. Forensic science can use this technique to estimate the age of a cadaver or an objet d'art to determine authenticity.
== Niger, Chad, Benin, CAR == Amadou Boubacar Cissé – politician, former prime minister, former Minister of State for Planning, Regional Development, and Community Development, Niger Mamadou Tandja (Fula/Soninke)- former president, Niger Hama Amadou – politician, former prime minister and president of the National Assembly of Niger Amadou Cheiffou – politician, former prime minister of Niger Albadé Abouba – politician, former acting prime minister, Current Minister of State, Minister of Agriculture and Livestock. Niger Bibata Niandou Barry - former Minister of women Affairs. Salifou Modi - former chief of staff, Nigerien Army, Vice President of the National Council for the Safeguard of the Homeland (Military Junta). Aissa Diori - former first lady, Niger Amina Bazindre - former ambassador to romania, Hungary, Germany and Russia. Fatou Djibo - author, first Nigerian woman to drive a car. Bouli Ali Diallo - academic, activist. Abdou Abarry - Nigerian diplomat, former president united nations security council, special representative for Central Africa and Head of the United Nations Regional Office for Central Africa. Ide Oumarou - diplomat, government minister, and journalist, former secretary-general of the Organization of African Unity Abdel Kader Baba-Laddé (or General Baba Laddé or Mahamat Abdoul Kadre) – politician, Chad. Aïchatou Boulama Kané - first female governor of Niamey, former minister of foreign affairs.
PMID 30938236.{{cite journal}}: CS1 maint: multiple names: authors list (link) Acharya, B; Wang, K; Kim, IS; Kang, W; Moon, C; Lee, BH (2013). "In vivo imaging of myocardial cell death using a peptide probe and assessment of long-term heart function". Journal of Controlled Release. 172 (1): 367–73. doi:10.1016/j.jconrel.2013.08.294. PMID 24021357. Acharya, B; Chun, SY; Kim, SY; Moon, C; Shin, HI; Park, EK (2012). "Surface immobilization of MEPE peptide onto HA/β-TCP ceramic particles enhances bone regeneration and remodeling". Journal of Biomedical Materials Research Part B: Applied Biomaterials. 100 (3): 841–9. doi:10.1002/jbm.b.32648. PMID 22278974. Choi, YA; Lim, J; Kim, KM; Acharya, B; Cho, JY; Bae, YC; Shin, HI; Kim, SY; Park, EK (2010). "Secretome analysis of human BMSCs and identification of SMOC1 as an important ECM protein in osteoblast differentiation". Journal of Proteome Research. 9 (6): 2946–56. doi:10.1021/pr901110q. PMID 20359165. He, X; Bonaparte, N; Kim, S; Acharya, B; Lee, JY; Chi, L; Lee, HJ; Paik, YK; Moon, PG; Baek, MC; Lee, EK; KIM, JH; KIM, IS; Lee, BH (2012). "Enhanced delivery of T cells to tumor after chemotherapy using membrane-anchored, apoptosis-targeted peptide". Journal of Controlled Release. 162 (6): 521–8. doi:10.1016/j.jconrel.2012.07.023. PMID 22824781. Venkatesha, S. H.; Dudics, S; Acharya, B; Moudgil, K. D. (2014). "Cytokine-Modulating Strategies and Newer Cytokine Targets for Arthritis Therapy". International Journal of Molecular Sciences. 16 (1): 887–906. doi:10.3390/ijms16010887. PMC 4307281. PMID 25561237.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.